Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 8/20 | 0.40 |
| ▸ | HTR1A | P08908 | 8/20 | 0.40 |
| ▸ | HTR2B | P41595 | 8/20 | 0.40 |
| ▸ | HTR5A | P47898 | 7/20 | 0.40 |
| ▸ | HTR6 | P50406 | 7/20 | 0.40 |
| ▸ | HTR1D | P28221 | 6/20 | 0.40 |
| ▸ | HTR1B | P28222 | 6/20 | 0.40 |
| ▸ | HTR2A | P28223 | 6/20 | 0.40 |
| ▸ | HTR2C | P28335 | 6/20 | 0.40 |
| ▸ | HTR1E | P28566 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2372578 | 0.85 | APP (0.47) | HTR7CA12CA1CA2CA4 | |
| SCHEMBL8124307 | 0.81 | CA1 (0.41) | HTR7CA12CA1CA2CA4 | |
| SCHEMBL7370333 | 0.79 | TP53 (0.52) | CA12CA1CA2CA4CA7 | |
| SCHEMBL8125032 | 0.79 | NFE2L2 (0.42) | HTR7CA12CA1CA2CA4 | |
| SCHEMBL3990580 | 0.79 | CYP2A6 (0.44) | L3MBTL1TSHRHSD17B10NPC1ALDH1A1 | |
| SCHEMBL2885322 | 0.79 | CA1 (0.50) | CA12CA1CA2CA4CA7 | |
| SCHEMBL8560761 | 0.77 | CYP2A6 (0.43) | L3MBTL1TSHRNPC1ALDH1A1TP53 | |
| SCHEMBL7084083 | 0.77 | MAPT (0.47) | CA12CA1CA2CA4CA7 | |
| SCHEMBL7006398 | 0.77 | CA1 (0.38) | CA12CA1CA2CA4CA7 | |
| SCHEMBL2027163 | 0.77 | APP (0.46) | HTR7CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2397462-A2 | Compounds, compositions and methods of treatment for heart failure | Cytokinetics, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20090176307-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-7491826-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7399866-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20060241110-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-10-26 | — | — | US | disclosed |
| US-20050159416-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241110-A1 | Compounds, compositions, and methods | TNNI3, TNNT2, TNNC1 | HTR7 2891/4885HTR1A 3787/4885HTR2B 3851/4885 |
| US-20050159416-A1 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | HTR7 3111/4885HTR1A 3992/4885HTR2B 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.